Publications

BibTex format

@inbook{Barnes:2023:10.1016/bs.apha.2023.04.001,
author = {Barnes, PJ},
doi = {10.1016/bs.apha.2023.04.001},
pages = {249--271},
title = {Senotherapy for lung diseases.},
url = {http://dx.doi.org/10.1016/bs.apha.2023.04.001},
year = {2023}
}

Download

RIS format (EndNote, RefMan)

TY  - CHAP
AB  - Increasing evidence suggests that there is acceleration of lung ageing in chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF), with the accumulation of senescent cells in the lung. Senescent cells fail to repair tissue damage and release an array of inflammatory proteins, known as the senescence-associated secretory phenotype, which drive further senescence and disease progression. This suggests that targeting cellular senescence with senotherapies may treat the underlying disease process in COPD and IPF and thus reduce disease progression and mortality. Several existing or future drugs may inhibit the development of cellular senescence which is driven by chronic oxidative stress (senostatics), including inhibitors of PI3K-mTOR signalling pathways, antagomirs of critical microRNAs and novel antioxidants. Other drugs (senolytics) selectively remove senescent cells by promoting apoptosis. Clinical studies with senotherapies are already underway in chronic lung diseases.
AU  - Barnes,PJ
DO  - 10.1016/bs.apha.2023.04.001
EP  - 271
PY  - 2023///
SP  - 249
TI  - Senotherapy for lung diseases.
UR  - http://dx.doi.org/10.1016/bs.apha.2023.04.001
UR  - https://www.ncbi.nlm.nih.gov/pubmed/37524489
ER  -

Download

Professor Sir Peter Barnes, FRS, FMedSci

Contact

Assistant

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)